Who are Five-days oseltamivir + baloxavir marboxil's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/five-days-oseltamivir-baloxavir-marboxil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Five-days oseltamivir + baloxavir marboxil — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Five-days oseltamivir + baloxavir marboxil (Five-days oseltamivir + baloxavir marboxil) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral combination (neuraminidase inhibitor + endonuclease inhibitor). Area: Infectious Disease / Virology.

phase 3 Antiviral combination (neuraminidase inhibitor + endonuclease inhibitor) Influenza neuraminidase; influenza cap-dependent endonuclease Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Five-days oseltamivir + baloxavir marboxil (Five-days oseltamivir + baloxavir marboxil) — UMC Utrecht. This combination uses two antiviral agents with different mechanisms to inhibit influenza virus replication through dual targeting of viral neuraminidase and cap-dependent endonuclease.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Five-days oseltamivir + baloxavir marboxil TARGET	Five-days oseltamivir + baloxavir marboxil	UMC Utrecht	phase 3	Antiviral combination (neuraminidase inhibitor + endonuclease inhibitor)	Influenza neuraminidase; influenza cap-dependent endonuclease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral combination (neuraminidase inhibitor + endonuclease inhibitor) class)

UMC Utrecht · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Five-days oseltamivir + baloxavir marboxil — Competitive Intelligence Brief. https://druglandscape.com/ci/five-days-oseltamivir-baloxavir-marboxil. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab